REGN

$927.8913.33%109.12

Dopo l'orario di chiusura: 926.00-1.89 -0.20%

Regeneron Pharmaceuticals Inc (REGN)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$818.77

Aprire:

$869.43

Volume 24 ore:

2,851,604

Volume relativo:

3.39

Capitalizzazione di mercato:

$95.53B

Reddito:

$14.92B

Utile/perdita netta:

$4.42B

Rapporto P/E:

22.61

EPS:

$41.04

Flusso di cassa netto:

$3.79B

1W Prestazione:

+15.26%

1M Prestazione:

+22.37%

6M Prestazione:

+31.23%

1Y Prestazione:

+41.87%

Intervallo 1D:

$839.08$935.35

Intervallo di 1 settimana:

$796.61$935.35

Portata 52W:

$591.52$935.35

Profilo aziendale di Regeneron Pharmaceuticals Inc (REGN)

Nome

Regeneron Pharmaceuticals Inc

Settore

Healthcare

Industria

Biotechnology

Telefono

(914) 847-7000

Indirizzo

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, USA

Dipendente

15,410

@regeneron

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di REGN su X

Confronta REGN con VRTX, MRNA, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
REGN Regeneron Pharmaceuticals Inc	$927.89	$95.53B	$14.92B	$4.42B	$3.79B	$41.04
VRTX Vertex Pharmaceuticals Inc	$558.88	$141.65B	$12.34B	$4.34B	$3.71B	$16.87
MRNA Moderna Inc	$221.72	$88.52B	$2.23B	-$3.19B	-$1.60B	-$8.15
ARGX Argen X Se Adr	$892.87	$56.15B	$4.16B	$1.29B	$734.26M	$19.58
ONC Beone Medicines Ltd Adr	$370.33	$41.89B	$5.76B	$514.49M	$1.10B	$4.48

Regeneron Pharmaceuticals Inc Azioni (REGN) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-10-01	Aggiornamento	Argus	Hold → Buy
2026-05-18	Downgrade	Citigroup	Buy → Neutral
2026-05-18	Downgrade	Leerink Partners	Outperform → Market Perform
2026-03-31	Resumed	Piper Sandler	Overweight
2026-03-06	Iniziato	Barclays	Overweight
2026-01-07	Aggiornamento	BofA Securities	Underperform → Buy
2025-12-03	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-11-24	Iniziato	HSBC Securities	Buy
2025-11-24	Resumed	Truist	Buy
2025-11-13	Iniziato	Scotiabank	Sector Perform
2025-08-14	Iniziato	Rothschild & Co Redburn	Buy
2025-06-30	Downgrade	Argus	Buy → Hold
2025-05-30	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-05-14	Aggiornamento	Citigroup	Neutral → Buy
2025-04-22	Resumed	Cantor Fitzgerald	Overweight
2025-02-05	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-01-16	Downgrade	UBS	Buy → Neutral
2024-12-10	Resumed	BofA Securities	Underperform
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-11-14	Iniziato	Citigroup	Neutral
2024-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
2024-03-12	Iniziato	Bernstein	Outperform
2024-01-12	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-11-03	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-08-21	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-08-21	Reiterato	Oppenheimer	Perform
2023-06-28	Downgrade	Canaccord Genuity	Buy → Hold
2023-03-27	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-24	Aggiornamento	Jefferies	Hold → Buy
2023-03-23	Aggiornamento	Raymond James	Underperform → Mkt Perform
2023-01-30	Aggiornamento	Cowen	Market Perform → Outperform
2023-01-20	Aggiornamento	JP Morgan	Neutral → Overweight
2022-10-26	Downgrade	Raymond James	Mkt Perform → Underperform
2022-10-17	Downgrade	Evercore ISI	Outperform → In-line
2022-09-09	Aggiornamento	Jefferies	Underperform → Hold
2022-09-09	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-06	Iniziato	Jefferies	Underperform
2022-05-23	Iniziato	SVB Leerink	Outperform
2022-01-05	Downgrade	BofA Securities	Neutral → Underperform
2022-01-03	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-12-15	Downgrade	Bernstein	Outperform → Mkt Perform
2021-12-09	Resumed	Wells Fargo	Overweight
2021-12-07	Resumed	Cowen	Market Perform
2021-12-06	Iniziato	Goldman	Buy
2021-11-19	Resumed	BMO Capital Markets	Outperform
2021-11-05	Downgrade	The Benchmark Company	Buy → Hold
2021-06-29	Iniziato	H.C. Wainwright	Buy
2021-01-25	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Aggiornamento	The Benchmark Company	Hold → Buy
2021-01-08	Aggiornamento	Citigroup	Neutral → Buy
2020-10-05	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Downgrade	The Benchmark Company	Buy → Hold
2020-07-09	Aggiornamento	SunTrust	Hold → Buy
2020-05-26	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-04-28	Downgrade	Citigroup	Buy → Neutral
2020-04-17	Aggiornamento	The Benchmark Company	Hold → Buy
2020-04-08	Iniziato	The Benchmark Company	Hold
2020-03-31	Iniziato	Wolfe Research	Peer Perform
2020-02-27	Iniziato	Barclays	Overweight
2020-02-26	Aggiornamento	Canaccord Genuity	Hold → Buy
2020-02-26	Downgrade	Robert W. Baird	Outperform → Neutral
2020-02-25	Aggiornamento	Jefferies	Hold → Buy
2020-02-11	Aggiornamento	Argus	Hold → Buy
2019-12-24	Iniziato	Raymond James	Mkt Perform
2019-12-16	Downgrade	Evercore ISI	Outperform → In-line
2019-12-13	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-11-12	Iniziato	SunTrust	Hold
2019-11-07	Aggiornamento	Citigroup	Neutral → Buy
2019-10-17	Resumed	BofA/Merrill	Neutral
2019-09-23	Aggiornamento	Guggenheim	Neutral → Buy

Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading

Guarini KathrynOct 30 '26
Director
Transazione
Proposed Sale
Costo
$900.00
#Azioni
400
Valore ($)
360,000
#Azioni Totale
0
McCourt MarionOct 30 '26
Officer
Transazione
Proposed Sale
Costo
$869.43
#Azioni
1,132
Valore ($)
984,195
#Azioni Totale
0
MURPHY ANDREW JOct 14 '26
Officer
Transazione
Proposed Sale
Costo
$772.70
#Azioni
4,147
Valore ($)
3,204,380
#Azioni Totale
0
MURPHY ANDREW JOct 14 '26
Co-Chief Scientific Officer
Transazione
Sale
Costo
$772.70
#Azioni
4,147
Valore ($)
3,204,376
#Azioni Totale
47,833
MURPHY ANDREW JOct 13 '26
Co-Chief Scientific Officer
Transazione
Option Exercise
Costo
$381.92
#Azioni
17,000
Valore ($)
6,492,640
#Azioni Totale
64,833
McCourt MarionSep 03 '26
Officer
Transazione
Proposed Sale
Costo
$857.00
#Azioni
1,131
Valore ($)
969,267
#Azioni Totale
0
McCourt MarionSep 03 '26
EVP Commercial
Transazione
Sale
Costo
$857.39
#Azioni
1,131
Valore ($)
969,708
#Azioni Totale
12,003
Guarini KathrynSep 02 '26
Director
Transazione
Proposed Sale
Costo
$850.00
#Azioni
400
Valore ($)
340,000
#Azioni Totale
0
McCourt MarionSep 02 '26
Officer
Transazione
Proposed Sale
Costo
$850.00
#Azioni
1,215
Valore ($)
1,032,750
#Azioni Totale
0
Guarini KathrynSep 02 '26
Director
Transazione
Sale
Costo
$850.00
#Azioni
400
Valore ($)
340,000
#Azioni Totale
603

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Guarini Kathryn	Director	Oct 30 '26	Proposed Sale	$900.00	400	360,000	0
McCourt Marion	Officer	Oct 30 '26	Proposed Sale	$869.43	1,132	984,195	0
MURPHY ANDREW J	Officer	Oct 14 '26	Proposed Sale	$772.70	4,147	3,204,380	0
MURPHY ANDREW J	Co-Chief Scientific Officer	Oct 14 '26	Sale	$772.70	4,147	3,204,376	47,833
MURPHY ANDREW J	Co-Chief Scientific Officer	Oct 13 '26	Option Exercise	$381.92	17,000	6,492,640	64,833
McCourt Marion	Officer	Sep 03 '26	Proposed Sale	$857.00	1,131	969,267	0
McCourt Marion	EVP Commercial	Sep 03 '26	Sale	$857.39	1,131	969,708	12,003
Guarini Kathryn	Director	Sep 02 '26	Proposed Sale	$850.00	400	340,000	0
McCourt Marion	Officer	Sep 02 '26	Proposed Sale	$850.00	1,215	1,032,750	0
Guarini Kathryn	Director	Sep 02 '26	Sale	$850.00	400	340,000	603

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

Oct 30, 2026

Pre-Markets in Red on Massive AI Spending Concerns - Zacks Investment Research

Oct 30, 2026

Pre-Markets Spooked on Questions Regarding AI, Oil Prices - Zacks Investment Research

Oct 30, 2026

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise - Zacks Investment Research

Oct 30, 2026

Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research

Oct 30, 2026

Oct 27, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT - GlobeNewswire Inc.

Oct 27, 2026

Oct 26, 2026

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research

Oct 26, 2026

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness - GlobeNewswire Inc.

Oct 26, 2026

Oct 25, 2026

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) - GlobeNewswire Inc.

Oct 25, 2026

Oct 23, 2026

Facing Investing Fears - The Motley Fool

Oct 23, 2026

Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Oct 23, 2026

Oct 22, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Newly Bought by Cantor Fitzgerald Investment Advisors L.P. - MarketBeat

Oct 22, 2026

Oct 21, 2026

Are You Overpaying For Regeneron Stock Versus Its Rivals? - Trefis

Oct 21, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD Cowen - MarketBeat

Oct 21, 2026

TD Cowen maintains Buy rating on Regeneron Pharmaceuticals, $980 price target - TradingView

Oct 21, 2026

Oct 20, 2026

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Oct 20, 2026

Oct 19, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Oct 19, 2026

EyePoint to halve workforce after experimental drug fails second late-stage trial - Reuters

Oct 19, 2026

Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results - Yahoo Finance

Oct 19, 2026

How Much Upside Is Left In Regeneron Stock? - Yahoo Finance

Oct 19, 2026

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool

Oct 19, 2026

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool

Oct 19, 2026

Oct 17, 2026

Regeneron Pharmaceuticals, Inc. (REGN) options chain - Yahoo Finance Australia

Oct 17, 2026

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share - The Motley Fool

Oct 17, 2026

Oct 16, 2026

Regeneron Pharmaceuticals, Inc. (REGN) options chain - Yahoo Finance UK

Oct 16, 2026

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types - GlobeNewswire Inc.

Oct 16, 2026

Oct 15, 2026

Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds - Yahoo Finance

Oct 15, 2026

Regeneron (REGN) Stock Still Looks Below Fair Value On Fresh Trial Data - Yahoo Finance

Oct 15, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 15, 2026

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research

Oct 15, 2026

Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research

Oct 15, 2026

What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report - Barchart.com

Oct 15, 2026

Oct 14, 2026

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research

Oct 14, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 14, 2026

Oct 13, 2026

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Oct 13, 2026

RBC raises target for Regeneron stock to USD 810.00 - ad-hoc-news.de

Oct 13, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 13, 2026

Regeneron reports 84-week Phase III data for Pasatru in adult FOP - Yahoo Finance

Oct 13, 2026

Regeneron reports Pasatru data and Citi holds Regeneron stock - ad-hoc-news.de

Oct 13, 2026

Regeneron presents new long-term data for Pasatru - The Pharma Letter

Oct 13, 2026

Regeneron reports 84-week Pasatru results: stock pre-market at EUR 684.95 - ad-hoc-news.de

Oct 13, 2026

Oct 12, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 12, 2026

Regeneron’s New Drug Halts Rogue Bone Growth Effectively - Regeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga

Oct 12, 2026

Regeneron Reports Sustained 84-Week Efficacy Data for Pasatru in Adults With FOP - Quiver Quantitative

Oct 12, 2026

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Oct 12, 2026

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month - Stocktwits

Oct 12, 2026

Oct 11, 2026

Should Alliance Expansion Require Action From Regeneron (REGN) Investors? - Simply Wall Street

Oct 11, 2026

Regeneron Pharmaceuticals, Inc. (REGN) options chain - Yahoo Finance Australia

Oct 11, 2026

Oct 10, 2026

Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative - Simply Wall Street

Oct 10, 2026

Oct 09, 2026

Why Regeneron (REGN) is a Top Value Stock for the Long-Term - Zacks Investment Research

Oct 09, 2026

Regeneron Pharma Is Maintained at Sector Perform by RBC Capital - Moomoo

Oct 09, 2026

Simile a REGN